Access the full text.
Sign up today, get DeepDyve free for 14 days.
(Japanese Circulation Society. Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf. 2017. Accessed 18 June 2022.)
Japanese Circulation Society. Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf. 2017. Accessed 18 June 2022.Japanese Circulation Society. Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf. 2017. Accessed 18 June 2022., Japanese Circulation Society. Guidelines for diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/09/JCS2017_ito_h.pdf. 2017. Accessed 18 June 2022.
M. Hume (1978)
Venous thrombosis: mechanisms and treatment.Advances in experimental medicine and biology, 102
G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus, M. Johnson, U. Masiukiewicz, R. Pak, J. Thompson, G. Raskob, J. Weitz (2013)
Oral apixaban for the treatment of acute venous thromboembolism.The New England journal of medicine, 369 9
Sfedu Ep, A. Bhatt, C. Fauth (2010)
[Acute pulmonary embolism. I].Cardiologia pratica, 19 4
M. Ota, M. Nakamura, N. Yamada, T. Yazu, K. Ishikura, N. Hiraoka, Hideki Tanaka, H. Fujioka, N. Isaka, T. Nakano (2002)
Prognostic significance of early diagnosis in acute pulmonary thromboembolism with circulatory failureHeart and Vessels, 17
(2021)
Virchow triad. Treasure Island: StatPearls
N. Yamada, K. Hanzawa, S. Ota, Mashio Nakamura, Koichi Sato, M. Ikura, Takeo Suzuki, T. Kaise, H. Nakajima, Masaaki Ito (2015)
Occurrence of Deep Vein Thrombosis among Hospitalized Non-Surgical Japanese Patients.Annals of vascular diseases, 8 3
M. Sakon, Y. Maehara, Hiroyuki Yoshikawa, H. Akaza (2006)
Incidence of venous thromboembolism following major abdominal surgery: a multi‐center, prospective epidemiological study in JapanJournal of Thrombosis and Haemostasis, 4
(Kushner A, West WP, Pillarisetty LS. Virchow triad. Treasure Island: StatPearls; 2021.)
Kushner A, West WP, Pillarisetty LS. Virchow triad. Treasure Island: StatPearls; 2021.Kushner A, West WP, Pillarisetty LS. Virchow triad. Treasure Island: StatPearls; 2021., Kushner A, West WP, Pillarisetty LS. Virchow triad. Treasure Island: StatPearls; 2021.
S. Kahn, W. Lim, A. Dunn, M. Cushman, F. Dentali, E. Akl, E. Akl, D. Cook, A. Balekian, Russell Klein, Hoang Le, Hoang Le, S. Schulman, M. Murad (2012)
Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
S. Normand, M. Landrum, E. Guadagnoli, J. Ayanian, J. Ayanian, T. Ryan, P. Cleary, B. Mcneil, B. Mcneil (2001)
Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.Journal of clinical epidemiology, 54 4
M Morrow, D Lynch-Smith (2022)
Factor V Leiden: development of VTE in surgery and trauma patients: a systematic reviewDimens Crit Care Nurs, 41
(Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22.)
Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22.Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22., Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–22.
(2022)
Development of VTE in Surgery and Trauma Patients: A Systematic Review
(Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: an observational study of nationwide time-series trends in Japan. Cardiol Ther. 2022;11(4):589–609.)
Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: an observational study of nationwide time-series trends in Japan. Cardiol Ther. 2022;11(4):589–609.Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: an observational study of nationwide time-series trends in Japan. Cardiol Ther. 2022;11(4):589–609., Takahashi S, Imura M, Katada J. Epidemiology and treatment patterns of venous thromboembolism: an observational study of nationwide time-series trends in Japan. Cardiol Ther. 2022;11(4):589–609.
Y Yamaguchi, T Fuji, M Akagi (2015)
The epidemiological study of venous thromboembolism and bleeding events using a Japanese healthcare database—validation studyJpn J Drug Inform, 17
(2011)
Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009).Circulation journal : official journal of the Japanese Circulation Society, 75 5
A. Nicolaides, J. Fareed, A. Kakkar, A. Comerota, S. Goldhaber, R. Hull, K. Myers, M. Samama, J. Fletcher, E. Kalodiki, D. Bergqvist, J. Bonnar, J. Caprini, C. Carter, J. Conard, B. Eklof, I. Elalamy, G. Gerotziafas, G. Geroulakos, A. Giannoukas, I. Greer, M. Griffin, S. Kakkos, M. Lassen, G. Lowe, A. Markel, P. Prandoni, G. Raskob, A. Spyropoulos, A. Turpie, J. Walenga, D. Warwick (2013)
Prevention and treatment of venous thromboembolism--International Consensus Statement.International angiology : a journal of the International Union of Angiology, 32 2
H. Büller, H. Décousus, M. Grosso, M. Mercuri, S. Middeldorp, M. Prins, G. Raskob, S. Schellong, L. Schwocho, A. Segers, M. Shi, P. Verhamme, P. Wells (2013)
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.The New England journal of medicine, 369 15
D. Anderson, G. Morgano, Carole Bennett, F. Dentali, C. Francis, D. Garcia, S. Kahn, Maryam Rahman, A. Rajasekhar, F. Rogers, M. Smythe, K. Tikkinen, A. Yates, Tejan Baldeh, S. Balduzzi, J. Brożek, I. Ikobaltzeta, H. Johal, I. Neumann, W. Wiercioch, J. Yepes-Nuñez, H. Schünemann, P. Dahm (2019)
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.Blood advances, 3 23
(Ouellettee, DR. Pulmonary embolism (PE). 2020. https://emedicine.medscape.com/article/300901.)
Ouellettee, DR. Pulmonary embolism (PE). 2020. https://emedicine.medscape.com/article/300901.Ouellettee, DR. Pulmonary embolism (PE). 2020. https://emedicine.medscape.com/article/300901., Ouellettee, DR. Pulmonary embolism (PE). 2020. https://emedicine.medscape.com/article/300901.
M. Sakuma, Mashio Nakamura, N. Yamada, S. Ota, K. Shirato, T. Nakano, Masaaki Ito, Takao Kobayashi (2009)
Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone.Circulation journal : official journal of the Japanese Circulation Society, 73 2
Takuhiro Yamaguchi, T. Fuji, M. Akagi, Y. Abe, Mashio Nakamura, N. Yamada, E. Oda, D. Matsubayashi, K. Ota, Masafumi Kobayashi, D. Matsui, Jumpei Kaburagi, Y. Matsushita, Atsushi Harada (2015)
The Epidemiological Study of Venous Thromboembolism and Bleeding Events Using a Japanese Healthcare Database, 17
J. Heit, M. Silverstein, M. Silverstein, D. Mohr, T. Petterson, W. O'fallon, L. Melton (2000)
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.Archives of internal medicine, 160 6
VF Tapson (2008)
Acute pulmonary embolismN Eng J Med, 358
P. Scicchitano, M. Tucci, M. Bellino, F. Cortese, A. Cecere, M. Palo, F. Massari, P. Caldarola, F. Silvestris, M. Ciccone (2020)
The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological InsightCardiovascular Drugs and Therapy
Shoko Takahashi, Miki Imura, J. Katada (2022)
Epidemiology and Treatment Patterns of Venous Thromboembolism: an Observational Study of Nationwide Time-Series Trends in JapanCardiology and Therapy, 11
G. Landman, R. Gans (2011)
Oral rivaroxaban for symptomatic venous thromboembolism.The New England journal of medicine, 364 12
A. Khorana, G. Connolly (2009)
Assessing risk of venous thromboembolism in the patient with cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 29
Y. Ohashi, M. Ikeda, H. Kunitoh, M. Sasako, T. Okusaka, H. Mukai, K. Fujiwara, Mashio Nakamura, M. Oba, T. Kimura, Kei Ibusuki, M. Sakon (2020)
Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE RegistryJapanese Journal of Clinical Oncology, 50
G. Connolly, C. Francis (2013)
Cancer-associated thrombosis.Hematology. American Society of Hematology. Education Program, 2013
T. Fuji, M. Akagi, Y. Abe, E. Oda, D. Matsubayashi, K. Ota, Masafumi Kobayashi, Y. Matsushita, Jumpei Kaburagi, Kei Ibusuki, A. Takita, Mikio Iwashita, Takuhiro Yamaguchi (2017)
Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare databaseJournal of Orthopaedic Surgery and Research, 12
A. Aggarwal, F. Rickles (2016)
Global public awareness of venous thromboembolism: commentJournal of Thrombosis and Haemostasis, 14
Mashio Nakamura, H. Fujioka, N. Yamada, T. Nakano, M. Sakuma, O. Okada, T. Kuriyama, N. Nakanishi, Y. Miyahara, T. Kunieda, T. Sugimoto (2001)
Clinical characteristics of acute pulmonary thromboembolism in Japan: Results of a multicenter registry in the japanese society of pulmonary embolism researchClinical Cardiology, 24
P. Wells, C. Owen, S. Doucette, D. Fergusson, Huyen Tran (1998)
Does this patient have deep vein thrombosis?JAMA, 295 2
Christina Fanola, F. Norby, A. Shah, P. Chang, P. Lutsey, W. Rosamond, M. Cushman, A. Folsom (2020)
Incident Heart Failure and Long-Term Risk for Venous Thromboembolism.Journal of the American College of Cardiology, 75 2
F. Cortese, P. Scicchitano, M. Gesualdo, G. Ricci, S. Carbonara, C. Franchini, Brigida Schiavone, F. Corbo, M. Ciccone (2017)
Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure.Current medicinal chemistry, 24 34
Y. Tsubata, T. Hotta, K. Hamai, N. Furuya, T. Yokoyama, R. Saito, A. Nakamura, T. Masuda, M. Hamaguchi, S. Kuyama, R. Honda, Tadashi Senoo, M. Nakanishi, M. Yamasaki, N. Ishikawa, K. Fujitaka, T. Kubota, H. Ohtsu, K. Kobayashi, T. Isobe (2021)
Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study)Therapeutic Advances in Medical Oncology, 14
R Bauersachs, SD Berkowitz, B Brenner (2010)
Oral rivaroxaban for symptomatic venous thromboembolismN Eng J Med, 363
IntroductionEvidence regarding the development of pulmonary thromboembolism (PE) during hospitalization is unclear. We hypothesized that the incidence of PE could vary depending on clinical department and aimed to conduct a survey on the incidence of in-hospital PE.MethodsWe conducted a retrospective analysis using claims data of in-hospital patients in Japan. We collected background information regarding patients with and without PE occurrence during hospitalization. Further, we determined the incidence of PE and implemented prophylactic procedures in patients with and without surgery according to clinical department at admission. Finally, we examined the duration of hospital stay and in-hospital mortality rates in patients with and without PE.ResultsWe found that 5007 (0.107%, 20.61 per 1000 person-years) patients developed PE during hospitalization and differed by clinical department at admission. Moreover, 2272 (0.095%, 19.3 per 1000 person-years) and 2735 (0.119%, 21.8 per 1000 person-years) patients with and without surgery, respectively, developed PE during hospitalization (P < 0.001). Further, 33.8% of inpatients underwent prophylactic procedures for PE; however, the implementation rate differed between patients with and without surgery (59.2% vs. 7.3%, P < 0.001). The median duration of hospital stay in patients with and without PE was 31.0 and 11.0 days, and the in-hospital mortality rates in patients with and without PE were 11.0% and 3.5%, respectively (P < 0.001).DiscussionThe incidence of in-hospital PE differed according to patient characteristics, clinical departments, and presence/absence of surgery. The onset of PE during hospitalization leads to prolonged hospital stay and in-hospital death.ConclusionIt is important to conduct a proper risk assessment on admission as well as to implement proper prophylactic procedures to prevent the development of PE during hospitalization.
Cardiology and Therapy – Springer Journals
Published: Mar 1, 2023
Keywords: Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism; Inpatients; In-hospital mortality
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.